BioVentrix Revivent TC™ System Clinical Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02931240 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 13, 2016
Last Update Posted : January 26, 2023
|
Sponsor:
BioVentrix
Information provided by (Responsible Party):
BioVentrix
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocation ratio. This study will include 126 patients of which 84 patients will be treated with the investigational device and 42 patients will be included in an active control group.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ventricular Dysfunction, Left | Device: Revivent TC | Not Applicable |
The Revivent TC System is indicated for patients referred for surgical treatment of left ventricular scar that is contiguous, and includes both anterior and septal components. Primary and Secondary Effectiveness Endpoints will compare data from the patients treated with the Revivent TC System to a control pool of patients who comply with all aspects of the protocol except scar location and are not treated with the investigational devices but remain on Guideline Directed Medical Therapy (GDMT). The primary safety and effectiveness endpoints will be evaluated at 12 months post procedure. The study will be conducted at a maximum of 20 clinical centers.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 126 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Clinical Study of the BioVentrix Revivent TC™ System for Treatment of Left Ventricular Aneurysms (ALIVE) |
| Actual Study Start Date : | August 29, 2017 |
| Estimated Primary Completion Date : | August 1, 2023 |
| Estimated Study Completion Date : | June 30, 2027 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment
Treatment with the Revivent TC System
|
Device: Revivent TC
Treatment of LV scar |
|
No Intervention: Control Pool
Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
|
Primary Outcome Measures :
- Incidence of all cause death, mechanical support, emergent cardiac surgery, prolonged mechanical ventilation, renal failure and clinically important stroke compared to data from the STS database for surgical LV aneurysm repair. [ Time Frame: 1 Month ]Composite primary safety endpoint of all cause death, placement of a mechanical support device intra or post-op (IABP, VAD, ECMO or catheter based), emergent cardiac surgery including reoperation for bleeding or tamponade, prolonged mechanical ventilation, renal failure and clinically important stroke (Rankin Score of 4 or higher) through 30-days post procedure. Data from the patients treated with the Revivent TC System will be compared to surgical outcomes data from the Society for Thoracic Surgery database for surgical LV aneurysm repair.
- The rate of all cause of death, mechanical support, and operation (or re-operation) for HF, bleeding or tamponade from 1 through 12 months post procedure compared to untreated patients who remain on Guideline Directed Medical Therapy (GDMT). [ Time Frame: 1 Year ]A composite of all cause of death, placement of a mechanical support device and operation (or re-operation) for HF, bleeding or tamponade from 1 through 12 months (day 31 through 365) post procedure. Data from patients treated with the Revivent TC System will be compared to data from a control pool of patients who comply with all aspects of the protocol except scar (aneurysm) location and are not treated with the investigational devices remain on Guideline Directed Medical Therapy (GDMT). Patients in the GDMT group will be evaluated from day 31 through 365 after the date of enrollment into the study.
Secondary Outcome Measures :
- The rate of re-hospitalization and improvement of HF Symptoms in patients treated with the test device compared to patients who are maintained on Guideline Directed Medical Therapy. [ Time Frame: 1 year ]
Composite primary effectiveness endpoint consisting of:
- No hospital readmission for new or worsening heart failure, and
- Improvement in MLHF Quality of Life score by >10 points, and
- Improvement in 6 Minute Walk Distance by >25 meters, and
- Improvement in NYHA Classification > 1 grade.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 18 years old or older
- LV Aneurysm or Scar Presence: Defined by presence of a contiguous acontractile (akinetic and/or dyskinetic) scar;
- LV Aneurysm/Scar Location: Defined as a scar involving septum and/or anterior, apical or anterolateral regions of the left ventricle as evidenced by cardiac imaging and referred for surgical management;
- Viability of myocardium in regions remote from area of intended scar exclusion as evidenced by cardiac imaging;
- Left Ventricular Ejection Fraction < 45%;
- Left ventricular end-systolic volume index ≥50 mL/m2;
- Suffering from heart failure symptoms as defined by NYHA Classification > 2 not responsive to medical therapy;
- Patient completed 6 Minute Walk Test and MLHF Quality of Life Questionnaire (can be performed at baseline visit);
- Patient is on adequate Guideline Directed Medical Therapy (GDMT);
- Subject or a legally authorized representative must provide written informed consent;
- Agree to required follow-up visits; and
- Female subject of childbearing potential does not plan pregnancy for at least one year following the index procedure. For a female of childbearing potential, a pregnancy test must be performed with negative results known within seven days prior to index procedure Candidates for the study group must meet ALL of the inclusion criteria.
Candidates allocated to active concurrent control pool of patients must meet all inclusion criteria (including LV Aneurysm/Scar Presence), WITH THE EXCEPTION OF ONE OF THE FOLLOWING:
- They have undergone previous pericardiotomy, left thoracotomy, or open heart surgery, or
- The LV Aneurysm/Scar location does not permit treatment with the study device, or
- The patient elects to be enrolled in the control group
Exclusion Criteria:
Candidates will be excluded from the study and active concurrent control group if ANY of the following conditions are present:
- Cardiac Resynchronization Therapy (CRT) or ICD pacing lead placement ≤ 60 days prior to enrollment;
- Valvular heart disease, which in the opinion of the investigator, will require surgery;
- Functional Mitral Regurgitation greater than moderate (i.e. EROA>20mm sq.) and degenerative MR (including MR due to papillary muscle rupture);
- Need for coronary revascularization, in the opinion of the site investigator;
- Peak Systolic Pulmonary Arterial Pressure > 60 mm Hg via echo or right heart catheterization and/or evidence of cor pulmonale;
- Myocardial Infarction within 90 days prior to enrollment;
- Within the last six months, a prior CVA or TIA, or any intracranial hemorrhage, or any permanent neurologic deficit, or any known intracranial pathology;
- Co-morbid disease process with life expectancy of less than one year or active malignancy not in remission;
- Any solid organ transplant or is on waiting list for any solid organ transplant other than cardiac;
- Chronic renal failure with a serum creatinine >2.5 mg/dL and/or GFR<30ml/min;
- Subject is currently participating in another clinical trial that has not yet completed its primary endpoint;
- Presence of significant ventricular arrhythmias
The following exclusion criteria apply only to the treatment group and do not apply to the concurrent control cohort:
- Contraindication or inability to adhere to systemic anticoagulation;
- Known hypersensitivity or contraindication to device materials;
- Previous pericardiotomy or left thoracotomy;
- Pathology/previous surgery/radiation therapy of the right neck that would interfere with placement of a 14F delivery catheter;
- Prior open heart surgery or significant pericarditis;
- Calcified ventricular wall in the area of intended anchor implants as verified by cardiac imaging;
- Thrombus or intra-ventricular mass in the left atrium or ventricle as verified by cardiac imaging that has not been adequately treated with anticoagulant.
- Functioning pacemaker leads in antero-apical RV, which, in the opinion of the investigator, would interfere with anchor placement;
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02931240
Locations
Show 30 study locations
Sponsors and Collaborators
BioVentrix
Investigators
| Principal Investigator: | Andrew S Wechsler, MD | Drexel University College of Medicine | |
| Principal Investigator: | Gregg W Stone, MD | Icahn School of Medicine at Mount Sinai | |
| Principal Investigator: | Jerry D Estep, MD | The Cleveland Clinic |
Additional Information:
| Responsible Party: | BioVentrix |
| ClinicalTrials.gov Identifier: | NCT02931240 |
| Other Study ID Numbers: |
CIP-0066 |
| First Posted: | October 13, 2016 Key Record Dates |
| Last Update Posted: | January 26, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
Additional relevant MeSH terms:
|
Ventricular Dysfunction Ventricular Dysfunction, Left Heart Diseases Cardiovascular Diseases |